CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
Previous Symbol
CUSIPN/A
Phone41-61-228-7800
Debt
Debt-to-Equity RatioN/A
Current Ratio15.39
Quick Ratio15.39
Price-To-Earnings
Trailing P/E Ratio-19.12
Forward P/E Ratio-10.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$41 million
Price / Sales41.38
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.09 per share
Price / Book7.99
Profitability
EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-331.84%
Return on Equity-40.41%
Return on Assets-30.90%
Miscellaneous
Employees127
Outstanding Shares51,900,000
Market Cap$1.74 billion
OptionableOptionable
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Thursday, November, 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.33. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $2.64 million. Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm's revenue for the quarter was down 76.6% compared to the same quarter last year. During the same period last year, the business posted ($0.62) EPS. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
12 brokerages have issued 12-month price objectives for Crispr Therapeutics' shares. Their predictions range from $38.72 to $86.00. On average, they anticipate Crispr Therapeutics' stock price to reach $62.1022 in the next year. This suggests a possible upside of 90.0% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.
What is the consensus analysts' recommendation for Crispr Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.
Has Crispr Therapeutics been receiving favorable news coverage?
News stories about CRSP stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX) and Spark Therapeutics (ONCE).
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Mr. Michael John Tomsicek M.B.A, Chief Financial Officer (Age 52)
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
- Dr. Rodger Novak, Founder, Chairman & Pres (Age 51)
- Dr. Samarth Kulkarni, CEO & Director (Age 39)
- Dr. Chad Cowan, Scientific Founder
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (3.08%), Federated Investors Inc. PA (1.47%), BlackRock Inc. (1.50%), Credit Suisse AG (1.15%), Jennison Associates LLC (1.15%) and EcoR1 Capital LLC (0.96%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.
Which major investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Allianz Asset Management GmbH, Robeco Institutional Asset Management B.V., United Services Automobile Association, Ipswich Investment Management Co. Inc., Korea Investment CORP, D.A. Davidson & CO. and PNC Financial Services Group Inc.. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Kurt Von Emster, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.
Which major investors are buying Crispr Therapeutics stock?
CRSP stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Jennison Associates LLC, EcoR1 Capital LLC, Valiant Capital Management L.P., Global Thematic Partners LLC, Credit Suisse AG, Laurion Capital Management LP and Capital International Investors. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $32.69.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $1.74 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.
What is Crispr Therapeutics' official website?
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.
MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
